SCHEMBL1345869

SCHEMBL1345869

NC(=O)c1cccc(-c2ccc(CNCc3ccc(Cl)cc3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
CNR1 P21554 1/20 0.50
NR4A2 P43354 1/20 0.50
NR3C2 P08235 1/20 0.49
PARP1 P09874 1/20 0.49
ERN1 O75460 1/20 0.48
MAP4K4 O95819 2/20 0.47
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PLAU P00749 1/20 0.46
HDAC1 Q13547 1/20 0.46
EPHX2 P34913 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
FAAH O00519 1/20 0.46
SUCNR1 Q9BXA5 2/20 0.45
ATM Q13315 1/20 0.45
CSF1R P07333 1/20 0.45
FLT1 P17948 1/20 0.45
FLT3 P36888 1/20 0.45
RORC P51449 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1347660 0.91 MCHR1 (0.54) CNR1NR4A2NR3C2CYP2C9CYP2C19
SCHEMBL1348877 0.91 HDAC1 (0.59) CNR1NR3C2PARP1ERN1PLAU
Hydrochloric Acid SCHEMBL3340188 0.90 HDAC1 (0.57) CNR1NR3C2PARP1ERN1PLAU
SCHEMBL1347900 0.89 CNR1 (0.55) CNR1NR3C2ERN1HDAC1EPHX2
SCHEMBL1347791 0.88 SLC6A2 (0.49) CNR1NR3C2PARP1ERN1HDAC1
SCHEMBL13929187 0.87 ERN1 (0.52) CNR1NR3C2PARP1ERN1HDAC1
SCHEMBL3723969 0.87 PARP1 (0.63) CNR1NR4A2PARP1ERN1MAP4K4
SCHEMBL1345554 0.86 DPP4 (0.52) CNR1NR3C2PARP1ERN1EPHX2
SCHEMBL1788320 0.86 HDAC1 (0.52) ALDH1A1CNR1HDAC1FAAH
SCHEMBL13335601 0.86 KDM4E (0.53) ALDH1A1CNR1NR3C2ERN1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US claimed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
WO-2009030962-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS OPRM1, OPRL1, OPRD1 ALDH1A1 751/4885CNR1 54/4885NR4A2 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.